Legis Daily

Advancing High Quality Treatment for Opioid Use Disorders in Medicare Act

USA115th CongressHR-5605| House 
| Updated: 6/20/2018
Raul Ruiz

Raul Ruiz

Democratic Representative

California

Cosponsors (2)
Marsha Blackburn (Republican)Greg Walden (Republican)

Ways and Means Committee, Finance Committee, Health Subcommittee, Energy and Commerce Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Advancing High Quality Treatment for Opioid Use Disorders in Medicare Act (Sec. 2) This bill requires the Centers for Medicare & Medicaid Services (CMS) to carry out a demonstration program to: (1) increase access to opioid-use disorder treatment services for Medicare beneficiaries, (2) improve physical and mental health outcomes for such beneficiaries, and (3) reduce Medicare expenditures. Opioid-use disorder care teams of practitioners may apply for participation in the demonstration project. The CMS must establish a performance-based incentive payment for participants. (Sec. 3) The bill also requires prescriptions for controlled substances that are covered under the Medicare prescription drug benefit or Medicare Advantage prescription drug plans to be transmitted via electronic prescription programs. The CMS may waive such requirements under specified circumstances.

Bill Text Versions

View Text
4 versions available

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Apr 24, 2018
Introduced in House
Apr 24, 2018
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
May 1, 2018
Referred to the Subcommittee on Health.
May 17, 2018
Ordered to be Reported (Amended) by Voice Vote.
May 17, 2018
Committee Consideration and Mark-up Session Held.
Jun 12, 2018
Placed on the Union Calendar, Calendar No. 578.
Jun 12, 2018
Committee on Ways and Means discharged.
Jun 12, 2018
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 115-744, Part I.
Jun 19, 2018
Mr. Walden moved to suspend the rules and pass the bill, as amended.
Jun 19, 2018
Considered under suspension of the rules. (consideration: CR H5239-5243)
Jun 19, 2018
DEBATE - The House proceeded with forty minutes of debate on H.R. 5605.
Jun 19, 2018
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H5239-5241)
Jun 19, 2018
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5239-5241)
Jun 19, 2018
Motion to reconsider laid on the table Agreed to without objection.
Jun 19, 2018
The title of the measure was amended. Agreed to without objection.
Jun 20, 2018
Received in the Senate and Read twice and referred to the Committee on Finance.
  • April 24, 2018
    Introduced in House


  • April 24, 2018
    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.


  • May 1, 2018
    Referred to the Subcommittee on Health.


  • May 17, 2018
    Ordered to be Reported (Amended) by Voice Vote.


  • May 17, 2018
    Committee Consideration and Mark-up Session Held.


  • June 12, 2018
    Placed on the Union Calendar, Calendar No. 578.


  • June 12, 2018
    Committee on Ways and Means discharged.


  • June 12, 2018
    Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 115-744, Part I.


  • June 19, 2018
    Mr. Walden moved to suspend the rules and pass the bill, as amended.


  • June 19, 2018
    Considered under suspension of the rules. (consideration: CR H5239-5243)


  • June 19, 2018
    DEBATE - The House proceeded with forty minutes of debate on H.R. 5605.


  • June 19, 2018
    Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H5239-5241)


  • June 19, 2018
    On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5239-5241)


  • June 19, 2018
    Motion to reconsider laid on the table Agreed to without objection.


  • June 19, 2018
    The title of the measure was amended. Agreed to without objection.


  • June 20, 2018
    Received in the Senate and Read twice and referred to the Committee on Finance.

Health

Related Bills

  • HR 115-6: SUPPORT for Patients and Communities Act
  • HR 115-3528: Every Prescription Conveyed Securely Act
  • S 115-2460: A bill to amend title XVIII of the Social Security Act to require e-prescribing for coverage under part D of the Medicare program of prescription drugs that are controlled substances.
Congressional oversightDrug, alcohol, tobacco useDrug therapyDrug trafficking and controlled substancesGovernment studies and investigationsHealth care qualityHealth personnelHealth programs administration and fundingHome and outpatient careHospital careMedicareMental healthPerformance measurementPrescription drugsUser charges and fees

Advancing High Quality Treatment for Opioid Use Disorders in Medicare Act

USA115th CongressHR-5605| House 
| Updated: 6/20/2018
Advancing High Quality Treatment for Opioid Use Disorders in Medicare Act (Sec. 2) This bill requires the Centers for Medicare & Medicaid Services (CMS) to carry out a demonstration program to: (1) increase access to opioid-use disorder treatment services for Medicare beneficiaries, (2) improve physical and mental health outcomes for such beneficiaries, and (3) reduce Medicare expenditures. Opioid-use disorder care teams of practitioners may apply for participation in the demonstration project. The CMS must establish a performance-based incentive payment for participants. (Sec. 3) The bill also requires prescriptions for controlled substances that are covered under the Medicare prescription drug benefit or Medicare Advantage prescription drug plans to be transmitted via electronic prescription programs. The CMS may waive such requirements under specified circumstances.

Bill Text Versions

View Text
4 versions available

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Apr 24, 2018
Introduced in House
Apr 24, 2018
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
May 1, 2018
Referred to the Subcommittee on Health.
May 17, 2018
Ordered to be Reported (Amended) by Voice Vote.
May 17, 2018
Committee Consideration and Mark-up Session Held.
Jun 12, 2018
Placed on the Union Calendar, Calendar No. 578.
Jun 12, 2018
Committee on Ways and Means discharged.
Jun 12, 2018
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 115-744, Part I.
Jun 19, 2018
Mr. Walden moved to suspend the rules and pass the bill, as amended.
Jun 19, 2018
Considered under suspension of the rules. (consideration: CR H5239-5243)
Jun 19, 2018
DEBATE - The House proceeded with forty minutes of debate on H.R. 5605.
Jun 19, 2018
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H5239-5241)
Jun 19, 2018
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5239-5241)
Jun 19, 2018
Motion to reconsider laid on the table Agreed to without objection.
Jun 19, 2018
The title of the measure was amended. Agreed to without objection.
Jun 20, 2018
Received in the Senate and Read twice and referred to the Committee on Finance.
  • April 24, 2018
    Introduced in House


  • April 24, 2018
    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.


  • May 1, 2018
    Referred to the Subcommittee on Health.


  • May 17, 2018
    Ordered to be Reported (Amended) by Voice Vote.


  • May 17, 2018
    Committee Consideration and Mark-up Session Held.


  • June 12, 2018
    Placed on the Union Calendar, Calendar No. 578.


  • June 12, 2018
    Committee on Ways and Means discharged.


  • June 12, 2018
    Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 115-744, Part I.


  • June 19, 2018
    Mr. Walden moved to suspend the rules and pass the bill, as amended.


  • June 19, 2018
    Considered under suspension of the rules. (consideration: CR H5239-5243)


  • June 19, 2018
    DEBATE - The House proceeded with forty minutes of debate on H.R. 5605.


  • June 19, 2018
    Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H5239-5241)


  • June 19, 2018
    On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5239-5241)


  • June 19, 2018
    Motion to reconsider laid on the table Agreed to without objection.


  • June 19, 2018
    The title of the measure was amended. Agreed to without objection.


  • June 20, 2018
    Received in the Senate and Read twice and referred to the Committee on Finance.
Raul Ruiz

Raul Ruiz

Democratic Representative

California

Cosponsors (2)
Marsha Blackburn (Republican)Greg Walden (Republican)

Ways and Means Committee, Finance Committee, Health Subcommittee, Energy and Commerce Committee

Health

Related Bills

  • HR 115-6: SUPPORT for Patients and Communities Act
  • HR 115-3528: Every Prescription Conveyed Securely Act
  • S 115-2460: A bill to amend title XVIII of the Social Security Act to require e-prescribing for coverage under part D of the Medicare program of prescription drugs that are controlled substances.
  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Congressional oversightDrug, alcohol, tobacco useDrug therapyDrug trafficking and controlled substancesGovernment studies and investigationsHealth care qualityHealth personnelHealth programs administration and fundingHome and outpatient careHospital careMedicareMental healthPerformance measurementPrescription drugsUser charges and fees